SEARCH:   Advanced

Blood, 15 February 2004, Vol. 103, No. 4, pp. 1560-1563. Prepublished online as a Blood First Edition Paper on October 9, 2003; DOI 10.1182/blood-2003-04-1170. This Article Full Text (PDF) All Versions of this Article: 2003-04-1170v1 103/4/1560    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Carvallo, C. Articles by Childs, R. W Search for Related Content PubMed PubMed Citation Articles by Carvallo, C. Articles by Childs, R. W Social Bookmarking                   What's this? Submitted April 16, 2003 Accepted September 22, 2003 Prior chemotherapy and allograft CD34+ dose impact donor engraftment following nonmyeloablative allogeneic stem cell transplantation in solid tumor patients Cristian Carvallo, Nancy Geller, Roger Kurlander, Ramaprasad Srinivasan, Othon Mena, Takehito Igarashi, Linda M Griffith, W Marston Linehan, and Richard W Childs* Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA Office of Biostatistics Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA Department of Laboratory Medicine, Warren Magnuson Clinical Center, National Institutes of Health, Bethesda, MD, USA Department of Transfusion Medicine, Warren Magnuson Clinical Center, National Institutes of Health, Bethesda, MD, USA Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA * Corresponding author; email: childsr{at}nhlbi.nih.gov. Significant engraftment variability occurs among patients following nonmyeloablative hematopoietic cell transplantation. We analyzed the impact of multiple factors on donor myeloid and T-cell engraftment in 36 patients with metastatic tumors undergoing cyclophosphamide/fludarabine-based conditioning. Higher CD34+ doses facilitated donor myeloid engraftment while prior chemotherapy exposure facilitated both donor myeloid and T-cell engraftment. At day 30, median donor T-cell and myeloid chimerism was 98% and 76% respectively in those with prior chemotherapy versus 88% (p=0.008) and 26% (p<0.0001) in chemotherapy-naive patients. Donor myeloid chimerism at day 45 was predicted by prior chemotherapy exposure and the log10 of the CD34+ dose (adjusted R2=.47, p< 0.0001), while chemotherapy alone impacted donor T-cell engraftment. Patients with prior chemotherapy were more likely to develop acute grade II-IV GVHD (8/18) compared to chemotherapy-naive patients (2/18; p=0.031). Thus, tailoring the intensity of nonmyeloablative conditioning based on prior chemotherapy exposure is an important consideration in trial design. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: Y.-G. Yao, R. W. Childs, S. Kajigaya, J. P. McCoy Jr., and N. S. Young Mitochondrial DNA Sequence Heterogeneity of Single CD34+ Cells After Nonmyeloablative Allogeneic Stem Cell Transplantation Stem Cells, October 1, 2007; 25(10): 2670 - 2676. [Abstract] [Full Text] [PDF] M. Mohty, O. Avinens, C. Faucher, P. Viens, D. Blaise, and J.-F. Eliaou Predictive factors and impact of full donor T-cell chimerism after reduced intensity conditioning allogeneic stem cell transplantation Haematologica, July 1, 2007; 92(7): 1004 - 1006. [Abstract] [Full Text] [PDF] T. M. Cao, J. A. Shizuru, R. M. Wong, K. Sheehan, G. G. Laport, K. E. Stockerl-Goldstein, L. J. Johnston, M. J. Stuart, F. C. Grumet, R. S. Negrin, et al. Engraftment and survival following reduced-intensity allogeneic peripheral blood hematopoietic cell transplantation is affected by CD8+ T-cell dose Blood, March 15, 2005; 105(6): 2300 - 2306. [Abstract] [Full Text] [PDF]

	Copyright © 2003 by American Society of Hematology         Online ISSN: 1528-0020